|
Mutation Information
|
Mutation Site
|
T66I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Genotype/Subtype
|
B |
|
Relevant Drug
|
elvitegravir (EVG) |
|
Country
|
Finland |
Literature Information
|
PubMed PMID
|
28212411
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2017 |
|
Journal
|
PloS one |
|
Title
|
Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. |
|
Author
|
Abram ME,Ram RR,Margot NA,Barnes TL,White KL,Callebaut C,Miller MD |
|
Evidence
|
None of these pre-treatment integrase sequences contained primary integrase mutations most often associated with emergent EVG (T66I, E92Q, S147G, Q148R/H/K, and N155H) or RAL (Y143C/R/H, Q148H/K/R, and N155H) resistance.
|
|
|
HIV Mutation Detail Information